Dianthus | Affinity Screening

  • Get fast, non-stop, highly sensitive hit screening with Dianthus.2:55

    Get fast, non-stop, highly sensitive hit screening with Dianthus.

    Dianthus removes the complexity of binding interaction measurements for drug discovery screening. Find hits for any target type in any buffer or bioliquid, measure the tightest interactions down to pi

    Watch
  • Targeted protein degradation promises to lead the way to effective drugs for challenging targets

    Targeted protein degradation promises to lead the way to effective drugs for challenging targets

    Read
  • Because you demand fast, non-stop, highly sensitive hit screening.

    Because you demand fast, non-stop, highly sensitive hit screening.

    Read
  • Ready to tackle your challenging affinity screening?

    Discover tools you can use

    Learn more
  • High-throughput determination of protein affinities using unmodified peptide libraries in nanomolar scale

    High-throughput determination of protein affinities using unmodified peptide libraries in nanomolar scale

    Read
  • Improve your protein degrader design with new ways to discover E3 ligase ligands35:47

    Improve your protein degrader design with new ways to discover E3 ligase ligands

    Targeted protein degradation using molecular glues or proteolysis-targeting chimeras (PROTACs) is an increasingly important therapeutic modality, especially for undruggable targets. Even with candidat

    Watch
  • Fast Mek1 hit identification with TRIC technology correlates well with other biophysical methods

    Fast Mek1 hit identification with TRIC technology correlates well with other biophysical methods

    Read
  • Adventures in drug discovery - The quest for your best small molecule56:52

    Adventures in drug discovery - The quest for your best small molecule

    Are you working in the field of small molecule drug discovery? Join this webinar to explore the drug discovery workflow and discover tools that can help in your quest for the most promising lead com

    Watch
  • Understanding the nuances of targeted protein degradation59:35

    Understanding the nuances of targeted protein degradation

    Bifunctional degrader molecules (also known as PROTACs) and molecular glues recruit proteins to E3 ubiquitin ligases. The formation of a ternary complex between PROTAC, ligase, and the protein of inte

    Watch
  • Tackle undruggable targets by screening for binary and ternary PROTAC interactions using Dianthus

    Tackle undruggable targets by screening for binary and ternary PROTAC interactions using Dianthus

    Read
  • Are you building an effective protein degrader?

    Are you building an effective protein degrader?

    Read
  • Protein degraders show promising results in drug development pipelines. See what progress candidates have made.

    Protein degraders show promising results in drug development pipelines. See what progress candidates have made.

    There has been considerable and promising development in the field of targeted protein degradation (TPD) since the seminal discovery of PROTACs in 2001.1 The appeal of degraders like PROTACs lies...

    Read
  • Is your screening campaign stuck? 3 signs that it’s time to look for an alternative biophysical technology

    Is your screening campaign stuck? 3 signs that it’s time to look for an alternative biophysical technology

    Most labs dedicated to drug discovery — in big pharma, biopharma, or CROs — make it a priority to have an adequate lineup of instruments for their screening campaigns. They decide on what...

    Read
  • Going small to win big: Fragment-based screening in drug discovery

    Going small to win big: Fragment-based screening in drug discovery

    Read
  • Follow these 7 tips when pipetting small volumes to get consistent assay results

    Follow these 7 tips when pipetting small volumes to get consistent assay results

    If you’ve ever had to pipette really small volumes, such as what is required in 384-well plates, you’re definitely familiar with the frustrations that come along with it. The concentration alone...

    Read
  • 4 ways to help you overcome the limitations of current methods in neurodegenerative disease research

    4 ways to help you overcome the limitations of current methods in neurodegenerative disease research

    Read
  • 6  protein degradation conferences in 2021 you can’t afford to miss

    6 protein degradation conferences in 2021 you can’t afford to miss

    Conferences in 2021 will gather scientists and experts eager to discuss new discoveries in the emerging field of targeted protein degradation (TPD). Many transcription factors, scaffold proteins,...

    Read
  • 3 case studies on how to characterize challenging drug discovery targets — membrane proteins, peptide libraries, and PROTACs

    3 case studies on how to characterize challenging drug discovery targets — membrane proteins, peptide libraries, and PROTACs

    A caveat to a successful pharmaceutical industry in which many effective drugs have already been discovered is the notion that the high hanging fruits left unpicked come in the form of challenging...

    Read
  • The NanoTemper Story – Chapter 5: The Dianthus

    The NanoTemper Story – Chapter 5: The Dianthus

    Almost as soon as the Monolith launched, the handful of people that made up NanoTemper in those early days huddled around, brainstorming how to translate the technology into a well-based assay....

    Read
  • Tackle the high-hanging fruits in challenging drug discovery pipelines17:10

    Tackle the high-hanging fruits in challenging drug discovery pipelines

    There are a number of interesting drug targets that have a reputation of being especially difficult to study in biochemical or biophysical assays. Join us to learn how Dianthus can help you address t

    Watch
  • Fast molecular interaction screening of epigenetic gene regulator G9a with fragments from a large chemical space

    Fast molecular interaction screening of epigenetic gene regulator G9a with fragments from a large chemical space

    Read
  • loading
    Loading more...